The company noted that if the FDA approves its application, Imosidolimab could address a significant unmet medical need in this rare and life-threatening disorder.
Vanda Pharmaceuticals Inc. (VNDA) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application for Imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP).
Add Asianet Newsable as a Preferred Source
The company noted that if the FDA approves its application, Imsidolimab could address a significant unmet medical need in this rare and life-threatening disorder.
Vanda shares were up nearly 5% in Wednesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
